Formosa Laboratories Inc Total Liabilities
Formosa Laboratories Inc total liabilities. Based on the latest financial reports, Formosa Laboratories Inc (4746) has total liabilities worth NT$5.01 Billion TWD (≈ $157.97 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See Formosa Laboratories Inc defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Total Liabilities of Formosa Laboratories Inc (2009–2025)
Total liabilities of Formosa Laboratories Inc from 2009 to 2025. This chart illustrates how Formosa Laboratories Inc's total liabilities have evolved over time, based on quarterly financial data. Check Formosa Laboratories Inc asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Formosa Laboratories Inc Competitors by Total Liabilities
The table below lists competitors of Formosa Laboratories Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
BV Financial, Inc. Common Stock
NASDAQ:BVFL
|
USA | $727.22 Million |
|
Aplicaciones y Tratamiento de Sistemas S.A.
MC:ATSI
|
Spain | €78.36 Million |
|
Sri Rejeki Isman(Sritex)PT
JK:SRIL
|
Indonesia | Rp1.61 Billion |
|
Thrace Plastics Holding and Commercial S.A
AT:PLAT
|
Greece | €171.85 Million |
|
Krsnaa Diagnostics Limited
NSE:KRSNAA
|
India | Rs5.84 Billion |
|
Patriot Acquisition Corp.
NASDAQ:PTAC
|
USA | $7.88 Million |
|
BANK OF JIUJIANG H YC1
F:BJ8
|
Germany | €474.81 Billion |
|
CMC Corp
VN:CMG
|
Vietnam | ₫6.06 Trillion |
Liability Composition Analysis (2009–2025)
This chart breaks down Formosa Laboratories Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see balance sheet size of Formosa Laboratories Inc.
Liquidity & Leverage Metrics
Formosa Laboratories Inc Total Liabilities Ratios Explained
Formosa Laboratories Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.33 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.64 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.37 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Formosa Laboratories Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Formosa Laboratories Inc (2009–2025)
The table below shows the annual total liabilities of Formosa Laboratories Inc from 2009 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | NT$5.16 Billion ≈ $162.67 Million |
-1.63% |
| 2024-12-31 | NT$5.25 Billion ≈ $165.36 Million |
-3.27% |
| 2023-12-31 | NT$5.43 Billion ≈ $170.95 Million |
+9.52% |
| 2022-12-31 | NT$4.95 Billion ≈ $156.09 Million |
+12.22% |
| 2021-12-31 | NT$4.41 Billion ≈ $139.09 Million |
-11.70% |
| 2020-12-31 | NT$5.00 Billion ≈ $157.53 Million |
-2.93% |
| 2019-12-31 | NT$5.15 Billion ≈ $162.29 Million |
+23.60% |
| 2018-12-31 | NT$4.17 Billion ≈ $131.30 Million |
+32.68% |
| 2017-12-31 | NT$3.14 Billion ≈ $98.96 Million |
+19.39% |
| 2016-12-31 | NT$2.63 Billion ≈ $82.89 Million |
-12.13% |
| 2015-12-31 | NT$2.99 Billion ≈ $94.33 Million |
+12.76% |
| 2014-12-31 | NT$2.66 Billion ≈ $83.65 Million |
+7.27% |
| 2013-12-31 | NT$2.48 Billion ≈ $77.99 Million |
+4.83% |
| 2012-12-31 | NT$2.36 Billion ≈ $74.39 Million |
+91.41% |
| 2011-12-31 | NT$1.23 Billion ≈ $38.87 Million |
+25.63% |
| 2010-12-31 | NT$981.92 Million ≈ $30.94 Million |
+172.92% |
| 2009-12-31 | NT$359.78 Million ≈ $11.33 Million |
-- |
About Formosa Laboratories Inc
Formosa Laboratories, Inc., together with its subsidiaries, engages in the manufacture and sale of active pharmaceutical ingredients (APIs) and ultraviolet absorbers in India, the Netherlands, Japan, Germany, Taiwan, China, Switzerland, the United States, Canada, and internationally. It offers APIs in the areas of anticancer, vitamin D derivatives, anti-inflammatory and analgesic agents, immunomo… Read more